BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 10193409)

  • 1. Expression, purification and immunological characterization of the transforming protein E7, from cervical cancer-associated human papillomavirus type 16.
    Fernando GJ; Murray B; Zhou J; Frazer IH
    Clin Exp Immunol; 1999 Mar; 115(3):397-403. PubMed ID: 10193409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression of the human papillomavirus type 16L/E7 fusion protein in E. coli and observation of its immunogenicity in mice].
    Tian HW; Ye ZM; Lu ZH; Jao R; Bian T; Zhao L; Ruan L
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Jun; 20(2):33-7. PubMed ID: 16816859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient expression of modified human papillomavirus 16 e6/e7 fusion protein and the antitumor efficacy in a mouse model.
    Zhou X; Qian X; Zhao Q; Lu Y; Xiong M
    Biol Pharm Bull; 2004 Mar; 27(3):303-7. PubMed ID: 14993792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7.
    Chu NR; Wu HB; Wu T; Boux LJ; Siegel MI; Mizzen LA
    Clin Exp Immunol; 2000 Aug; 121(2):216-25. PubMed ID: 10931134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7.
    Nonn M; Schinz M; Zumbach K; Pawlita M; Schneider A; Dürst M; Kaufmann AM
    J Cancer Res Clin Oncol; 2003 Sep; 129(9):511-20. PubMed ID: 12905010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responses.
    Báez-Astúa A; Herráez-Hernández E; Garbi N; Pasolli HA; Juárez V; Zur Hausen H; Cid-Arregui A
    J Virol; 2005 Oct; 79(20):12807-17. PubMed ID: 16188983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Construction and identification of non-replication recombinant vaccinia virus co-expressing human papillomavirus type 16 L1/L2/E6/E7 proteins].
    Huang W; Tian HW; Ren J; Fan JT; Zhao L; Bian T; Lu ZH; Ruan L
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2005 Sep; 19(3):240-3. PubMed ID: 16261206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection.
    Cheung YK; Cheng SC; Sin FW; Xie Y
    Vaccine; 2004 Dec; 23(5):629-38. PubMed ID: 15542183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human papillomavirus 16 L1-E7 chimeric virus like particles show prophylactic and therapeutic efficacy in murine model of cervical cancer.
    Sharma C; Dey B; Wahiduzzaman M; Singh N
    Vaccine; 2012 Aug; 30(36):5417-24. PubMed ID: 22717329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7.
    Daemen T; Regts J; Holtrop M; Wilschut J
    Gene Ther; 2002 Jan; 9(2):85-94. PubMed ID: 11857066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.
    Daemen T; Pries F; Bungener L; Kraak M; Regts J; Wilschut J
    Gene Ther; 2000 Nov; 7(21):1859-66. PubMed ID: 11110419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human papillomavirus type 16 E7 DNA vaccine: mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and antitumor activity.
    Shi W; Bu P; Liu J; Polack A; Fisher S; Qiao L
    J Virol; 1999 Sep; 73(9):7877-81. PubMed ID: 10438884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A general purification protocol for E7 proteins from "high- and low-risk" human papillomavirus types expressed in the yeast Schizosaccharomyces pombe.
    Braspenning J; Manetti R; Zumbach K; Meschede W; Gissmann L; Tommasino M
    Protein Expr Purif; 1997 Jul; 10(2):192-201. PubMed ID: 9226715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refolding and purification of human papillomavirus type 16 E7-lacZ fusion protein expressed in Escherichia coli.
    Chinami M; Yuge K; Kawano K; Shingu M
    Protein Expr Purif; 1991; 2(2-3):175-8. PubMed ID: 1668271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
    Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
    Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization.
    Daemen T; Riezebos-Brilman A; Regts J; Dontje B; van der Zee A; Wilschut J
    Antivir Ther; 2004 Oct; 9(5):733-42. PubMed ID: 15535411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer.
    Liu DW; Tsao YP; Kung JT; Ding YA; Sytwu HK; Xiao X; Chen SL
    J Virol; 2000 Mar; 74(6):2888-94. PubMed ID: 10684306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA vaccine encoding endosome-targeted human papillomavirus type 16 E7 protein generates CD4+ T cell-dependent protection.
    Brulet JM; Maudoux F; Thomas S; Thielemans K; Burny A; Leo O; Bex F; Hallez S
    Eur J Immunol; 2007 Feb; 37(2):376-84. PubMed ID: 17274002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined prophylactic and therapeutic intranasal vaccination against human papillomavirus type-16 using different adeno-associated virus serotype vectors.
    Nieto K; Kern A; Leuchs B; Gissmann L; Müller M; Kleinschmidt JA
    Antivir Ther; 2009; 14(8):1125-37. PubMed ID: 20032542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C; Roden RBS; Kirnbauer R
    Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.